Harbio BioMed Public Relations
March 23, 2021
Since its establishment, Harbour BioMed (HBM) continues to grow leaps and bounds with its innovative technology and differentiated R&D pipeline that keeps making significant progress. To support this growth the company continues to build a stronger talent pool by promoting internal personal, while simultaneously bringing external expertise to fuel the growth. On December 10th, 2020, HBM completed its global offering and listing on the Hong Kong Stock Exchange, marking a new milestone of its development and expansion. With multiple assets in late-phase clinical trials, HBM has entered a new phase of commercialization in its lifecycle.
Harbour BioMed Appoints Mai-Jing Liao, PhD, as Chief Commercial Officer
To lead this phase, HBM has appointmented Mai-Jing Liao, PhD, to the position of Chief Commercial Officer. He will continue to report to Jingsong Wang, MD Founder, Chairman of Board and CEO. In his new role, Dr. Liao will be responsible for company’s commercialization efforts including but not limited to launch readiness, sales and marketing that will catapult HBM into a new critical stage.
As Co-founder of HBM, Dr. Liao has built strong capabilities in business development and product portfolio strategy within the company. Under his leadership, HBM achieved several business development milestones including technology out-licensing, in licensing of key clinical stage assets while building a team of people dedicated to furthering HBM’s vision. These achievements were crucial to accelerate HBM’s growth and transform it into a clinical stage company it is today. He will continue his role as Chief Business Officer till his replacement is on board.
The Company Also Names Vice President & Head of Commercial Launch
HBM also announced the appointment of Danny Wu, as Vice President and Head of Commercial Launch. Mr. Wu will directly report to Dr. Liao. In this role, Mr. Wu will be responsible for formulating commercial strategy, building commercial capability, and expanding the commercial team. Mr. Wu has over 20 years of pharmaceutical experience, serving companies including MSD, Pfizer and Roche with roles in Sales and Marketing. During his tenure at MSD, he established ANA business unit. Prior to joining Harbour, he was Head of Marketing and Medical Affairs Department at Simcere Pharmaceutical.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
For further information, please refer to www.harbourbiomed.com
Harbio BioMed Public Relations